CS219077B1 - Derivatives of the 6,11-dihydrodibenzo/b,e/thiepin-11-carbonitrile and the salts thereof - Google Patents
Derivatives of the 6,11-dihydrodibenzo/b,e/thiepin-11-carbonitrile and the salts thereof Download PDFInfo
- Publication number
- CS219077B1 CS219077B1 CS610681A CS610681A CS219077B1 CS 219077 B1 CS219077 B1 CS 219077B1 CS 610681 A CS610681 A CS 610681A CS 610681 A CS610681 A CS 610681A CS 219077 B1 CS219077 B1 CS 219077B1
- Authority
- CS
- Czechoslovakia
- Prior art keywords
- dihydrodibenzo
- carbonitrile
- benzene
- salts
- thiepine
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title claims description 6
- -1 4-methylpiperazino Chemical group 0.000 claims description 6
- 150000007522 mineralic acids Chemical class 0.000 claims description 3
- 150000007524 organic acids Chemical class 0.000 claims description 3
- 235000005985 organic acids Nutrition 0.000 claims description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 51
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 239000000203 mixture Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 230000008602 contraction Effects 0.000 description 8
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 230000002048 spasmolytic effect Effects 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-M oxalate(1-) Chemical compound OC(=O)C([O-])=O MUBZPKHOEPUJKR-UHFFFAOYSA-M 0.000 description 4
- 125000003006 2-dimethylaminoethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 3
- 229910001626 barium chloride Inorganic materials 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- VEFLKXRACNJHOV-UHFFFAOYSA-N 1,3-dibromopropane Chemical compound BrCCCBr VEFLKXRACNJHOV-UHFFFAOYSA-N 0.000 description 2
- WQMAANNAZKNUDL-UHFFFAOYSA-N 2-dimethylaminoethyl chloride Chemical compound CN(C)CCCl WQMAANNAZKNUDL-UHFFFAOYSA-N 0.000 description 2
- FWWOWPGPERBCNJ-UHFFFAOYSA-N 2-hydroxy-4-(2-hydroxyethoxy)-4-oxobutanoic acid Chemical compound OCCOC(=O)CC(O)C(O)=O FWWOWPGPERBCNJ-UHFFFAOYSA-N 0.000 description 2
- NYYRRBOMNHUCLB-UHFFFAOYSA-N 3-chloro-n,n-dimethylpropan-1-amine Chemical compound CN(C)CCCCl NYYRRBOMNHUCLB-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- HTZCNXWZYVXIMZ-UHFFFAOYSA-M benzyl(triethyl)azanium;chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC1=CC=CC=C1 HTZCNXWZYVXIMZ-UHFFFAOYSA-M 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- YQCZBDVYQPTZFJ-UHFFFAOYSA-N 6,11-dihydrobenzo[c][1]benzothiepine-11-carbonitrile Chemical compound C1SC2=CC=CC=C2C(C#N)C2=CC=CC=C21 YQCZBDVYQPTZFJ-UHFFFAOYSA-N 0.000 description 1
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- JUGOREOARAHOCO-UHFFFAOYSA-M acetylcholine chloride Chemical compound [Cl-].CC(=O)OCC[N+](C)(C)C JUGOREOARAHOCO-UHFFFAOYSA-M 0.000 description 1
- 229960004266 acetylcholine chloride Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000003113 alkalizing effect Effects 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000002920 convulsive effect Effects 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- UZVGSSNIUNSOFA-UHFFFAOYSA-N dibenzofuran-1-carboxylic acid Chemical compound O1C2=CC=CC=C2C2=C1C=CC=C2C(=O)O UZVGSSNIUNSOFA-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- PSLIMVZEAPALCD-UHFFFAOYSA-N ethanol;ethoxyethane Chemical compound CCO.CCOCC PSLIMVZEAPALCD-UHFFFAOYSA-N 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000000956 myotropic effect Effects 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 229960001789 papaverine Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000003408 phase transfer catalysis Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
R je dimethylamino- nebo 4-methylpiperazinoskupin-a, a jejich solí s farmaceuticky nezávadnými -anorganickými nebo organickými kyselinami.R is dimethylamino- or 4-methylpiperazino-a, and salts thereof with pharmaceutically acceptable inorganic or organic acids.
Látky vzorce I a jejich soli jsou spasmolytiky a vykazují krátkodobé hypotensivní působení. Pro svůj spasmolytický účinek přicházejí v úvahu, jako léčiva použitelná k odstraňování bolestivých stavů vznikajících křečovitými stahy hladkého svalstva, zejména gastrointestinálního systému.The compounds of formula I and their salts are spasmolytics and exhibit short-term hypotensive effects. Due to their spasmolytic effect, they are suitable as medicaments for the removal of painful conditions resulting from convulsive contractions of smooth muscle, in particular the gastrointestinal system.
Spasmolytický účinek látek podle vynálezu lze prokázat v testu na isolovaném krysím duodenu, jehož kontrakce se vyvolávají jednak konstantní dávkou acetylcholinchloridu, jednak baryumchloridu. Látky po2 dle vynálezu jsou účinné proti oběma typům kontrakcí, tj. jejich účinek je jak parášympatholytický, tak i myotropní.The spasmolytic effect of the compounds according to the invention can be demonstrated in an isolated rat duodenum test, whose contractions are induced both by a constant dose of acetylcholine chloride and by barium chloride. The compounds of the present invention are effective against both types of contractions, i.e. their effect is both parashympatholytic and myotropic.
ll-{2-Dimethylaminoethyl)-6,ll-dihy<drodibenzo(b,e)thiepin-ll-karbonitril, který byl testován ve formě oxalátu, má intravenosní toxicitu u myší, LD50 = 45 mg/kg. V koncentracích 1—IQ jUg/ml tlumí kontrakce isolovaného duodenu, vyvolávané acetylcholíhem i baryumchloridem, n-a 50 %. V dávce 7 mg/ /kg vyvolává krátkodobý pokles krevního tlaku u anestesovaných krys o 20—35 %.11- (2-Dimethylaminoethyl) -6,11-dihydrodibenzo (b, e) thiepine-11-carbonitrile, which was tested as oxalate, has an intravenous toxicity in mice, LD 50 = 45 mg / kg. At concentrations of 10-1 µg / ml, the isolated duodenum contractions induced by both acetylchloride and barium chloride attenuate n-a 50%. At a dose of 7 mg / / kg it causes a short-term decrease in blood pressure of 20-35% in anesthetized rats.
11- (3-Dimethylaminopropyl) -6,11-dihydrodibenzo(b,e)thiepin-ll-karbonitril byl testován rovněž jako- o-xalát. Jeho toxicita u myší, LD50 = 38 mg/kg i.v. Spasmolytický účinek je výraznější vůči acetylcholinovým kontrakcím a nastává již v koncentracích 0-,1— —1 jUg/m-1; vůči baryumchloridovým kontrakcím se dosahuje 5Q<% útlumu stahů koncentracemi 1—10 ^ug/ml, co-ž se přibližně rovná spasmolytickém-u účinku papaverinu. V i.v. dávce 7 mg/kg vyvolává krátkodobé poklesy krevního tlaku u krys.11- (3-Dimethylaminopropyl) -6,11-dihydrodibenzo (b, e) thiepine-11-carbonitrile was also tested as o-oxalate. Its toxicity in mice, LD50 = 38 mg / kg i.v. The spasmolytic effect is more pronounced with respect to acetylcholine contractions and occurs already at concentrations of 0 - 1 - 1 µg / m -1; with respect to barium chloride contractions, 50% of the contraction loss was achieved with concentrations of 1-10 µg / ml, approximately equivalent to the spasmolytic effect of papaverine. In i.v. dose of 7 mg / kg causes short-term decreases in blood pressure in rats.
11- [ 3- (4-Methylplperazino) propyl ] -6,11-dihydrodibenzoíbjejthiepin-ll-karbonitril byl testován jako hydrogenmaleínát. Jeho akutní toxicita u myší je 50 mg/kg i.v. (LDso). Spasmolytický účinek vůči oběma typům kontrakcí nastává v koncentracích 1—10 ^g/ml.11- [3- (4-Methylpiperazino) propyl] -6,11-dihydrodibenzo [b] thipin-11-carbonitrile was tested as hydrogen maleate. Its acute toxicity in mice is 50 mg / kg i.v. (LD 50). The spasmolytic effect on both types of contractions occurs at concentrations of 1-10 µg / ml.
. Látky vzorce I podle vynálezu se připravují postupy, které jsou podrobně popsány v příkladech provedení. Výchozí látkou je 6,11-dihydro dibenzo (b ,e ] thiepln-ll-kar bonitril, jehož příprava byla popsána v práci M. Rajšnera a spol., Colleet'. Czeeh. Chem. Commun. 44, 2536 (1973). Tento nitril se působením silných basí, s výhodou natriumhydridu nebo· natriumamidu, převede na příslušný karbanion, který se potom alkyluje aminolkyalhalogenidy obecného vzorce II,. The compounds of the formula I according to the invention are prepared by the processes described in detail in the examples. The starting material is 6,11-dihydro dibenzo [b, e] thiepline-11-carbonitrile, the preparation of which is described in M. Rajšner et al., Colleet., Czeeh. Chem. Commun., 44, 2536 (1973). This nitrile is converted by treatment with strong bases, preferably sodium hydride or sodium amide, to the corresponding carbanion, which is then alkylated with the aminolyl halides of the formula II,
Hal'(CH2)nR (II) kdeHal '(CH 2) n R (II) wherein
Hal je atom chloru nebo- bromu aHal is a chlorine or bromine atom and
R značí totéž jako ve vzorci I. Jako silné base lze použít též 50% hydro-xidu sodného, avšak potom je nutné pracovat za přítomnosti katalýza toru fázového přenosu, s výhodou .triQthylbenzylamoniumchloridu. Álkylaci lze provést též alkylendihalogenidy, tj. zejména 1,2-dihromethanem a 1,3-dibrompropanem a vzniklé 11-(halogenalkyl) deriváty se potom bez · isolace podrobí substituční reakci s dimethylarninem nebo· l-methylpiperazinem.R is the same as in formula I. 50% sodium hydroxide can also be used as the strong base, but then it is necessary to work in the presence of a phase transfer catalysis, preferably trisylbenzylammonium chloride. Alkylation can also be carried out with alkylenedihalides, in particular 1,2-dihromethane and 1,3-dibromopropane, and the resulting 11- (haloalkyl) derivatives are then subjected to a substitution reaction with dimethylamine or 1-methylpiperazine without isolation.
Látky podle vynálezu jsou basické povahy, které neutralisaci farmaceuticky nezávodnými anorganickými nebo organickými kyselinami poskytují příslušné soli, které jsou vhodnější k provádění farmakologických testů a k přípravě lékových forem než volné base. Ze solí se jako· dobře krystalující a mírně rozpustné ve vodě zvláště osvědčily kyselé oxaláty a maleináty.The compounds of the invention are basic in nature, which provide neutralization with pharmaceutically non-toxic inorganic or organic acids to provide the appropriate salts, which are more suitable for pharmacological testing and for the preparation of dosage forms than the free bases. Of the salts, acid oxalates and maleatees have proven to be particularly crystalline and slightly water-soluble.
Identita látek podle vynálezu, popsaných v příkladech provedení, byla zajištěna jednak analyticky, jednak všemi běžnými spektrálními metodami.The identity of the substances according to the invention described in the examples was ensured both analytically and by all conventional spectral methods.
Příklady provedeníExamples
P.r ík 1 a d l .P. 1 and d l.
_ i '11- (2-D'me-thylaininoe thyl) -6,11-dihydrodibenzo (b,e) thiepin-11- karbon1trii11- (2-Dimethylamino-ethyl) -6,11-dihydrodibenzo (b, e) thiepine-11-carbonitrile
Směs 4,75 g 6,'ll-dihydrodibenzo(b,e)thiepin-ll-karbonltrilu (literatura citována), 14,8 g 2-dimethylaminoethylchloridu, 0,3 g triethylbenzylamoniumchloridu a 20 g 50% roztoku hydroxidu sodného se míchá 6 hodin při 4)0—50 °C. Potom se zředí vodou a extrahuje se benzenem. Extrakt se promyje vodou a bascký produkt se z něj převede do vodné fáze protřepáním s přebytečnou zředěnou kyselinou chlorovodíkovou. Vodný roztok hydroehloridu spolu s vysoleným olejovitým hydrochloridem se oddělí, zalkalizuje se 20% roztokem hydroxidu sodného a uvolněná base se opět extrahuje benzenem. Extrakt se vysuší uhličitanem draselným· a odpaří. Surová olejovitá base se získá ve výtěžku 3,6 g. Neutralisaci kyselinou oxalovou v etheru se získá hydrogenoxalát, který krystaluje z 05% ethanolu jako hemihydrát a v čistém stavu taje při 172—176 °C.A mixture of 4.75 g of 6,11-dihydrodibenzo (b, e) thiepine-11-carbonltril (literature cited), 14.8 g of 2-dimethylaminoethyl chloride, 0.3 g of triethylbenzylammonium chloride and 20 g of 50% sodium hydroxide solution is stirred for 6 hours. hours at 4) 0 - 50 ° C. It is then diluted with water and extracted with benzene. The extract is washed with water and the Basque product is transferred from it to the aqueous phase by shaking with excess dilute hydrochloric acid. The aqueous hydrochloride solution together with the salted oily hydrochloride were separated, basified with 20% sodium hydroxide solution and the liberated base was again extracted with benzene. The extract was dried over potassium carbonate and evaporated. The crude oil base was obtained in a yield of 3.6 g. Neutralization with oxalic acid in ether gave the hydrogen oxalate, which crystallized from 05% ethanol as the hemihydrate and melted at 172-176 ° C in pure state.
Příklad 2Example 2
11-(2-Dimethylaminoethyl )-6,11-dihydrodibenzo(b,e]thiep'in-ll'11- (2-Dimethylaminoethyl) -6,11-dihydrodibenzo (b, e] thiepin-11 '
-karbon^ trii-carbon? trii
K roztoku 13,4 g 6,11-dihydrodibenzo(b,e)thiepin-l:l-karbonitrilu v 60 ml dimethylformamidu se za míchání v dusíkové atmosféře přidá 1,8 g 80% hydridu sodného. Směs se míchá 10 minut a potom se přidá 0,8 g 2-dimethylaminoethylchloridu. Směs se vyhřeje na 90 °C a při této teplotě se míchá 15 minut. Po- ochlazení se zředí vodou a extrahuje se benzenem. Bašický produkt se převede z benzenového extraktu do- vodné báze protřepáním s přebytečnou zředěnou kyselinou chlorovodíkovou a alkalisací kyselé vrstvy vodným amoniakem se uvolní přečištěná base. Isoluje se extrakcí benzenem a benzen se odpaří. Chromatografický homogenní olejovitá base se získá ve výtěžku 13,9 g a poskytuje hydrogenoxalát tající při 172—176 °C, identický s produktem 2 příkladu 1.To a solution of 13.4 g of 6,11-dihydrodibenzo (b, e) thiepine-1: 1-carbonitrile in 60 ml of dimethylformamide was added, under stirring under nitrogen, 1.8 g of 80% sodium hydride. The mixture was stirred for 10 minutes and then 0.8 g of 2-dimethylaminoethyl chloride was added. The mixture was heated to 90 ° C and stirred at this temperature for 15 minutes. The cooling was diluted with water and extracted with benzene. The basic product is converted from the benzene extract into an aqueous base by shaking with excess dilute hydrochloric acid and alkalizing the acidic layer with aqueous ammonia to release the purified base. It is isolated by extraction with benzene and the benzene is evaporated. Chromatographic homogeneous oily base is obtained in a yield of 13.9 g and yields hydrogen oxalate melting at 172-176 ° C, identical to the product 2 of Example 1.
Příklad 3Example 3
11-(3-Dimethylaminopropyl )-6,11-dihydrodibenzo(b,e)thiepin-ll-karbonitril11- (3-Dimethylaminopropyl) -6,11-dihydrodibenzo (b, e) thiepine-11-carbonitrile
Směs 20 g 50% roztoku hydroxidu sodného, 0,4 g triethylbenzylamoniumchloridu,Mixture of 20 g of 50% sodium hydroxide solution, 0,4 g of triethylbenzylammonium chloride,
4.75 g 6,ll-dihydrodibenzo(b,e) thiepin-11-karbonitrilu a 15,0 g 3-dimethylaminopropylchloridu se míchá 8 hodin při teplotě 40 až 50 °'C. Po zředění vodou se extrahuje benzenem a z benzenové fáze se basický produkt převede do vodné fáze protřepáním s přebytečnou 3tM-HCl. Kyselý vodný roztok se zalkalisuje 10% hydroxidem sodným a přečištěná base se isoluje extrakcí benzenem. Extrakt se vysuší uhličitanem draselným a odpaří. Olejovitá base se získá ve výtěžku4.75 g of 6,11-dihydrodibenzo (b, e) thiepine-11-carbonitrile and 15.0 g of 3-dimethylaminopropyl chloride were stirred at 40-50 ° C for 8 hours. After dilution with water, it is extracted with benzene and from the benzene phase the basic product is transferred to the aqueous phase by shaking with excess 3 mM HCl. The acidic aqueous solution was made alkaline with 10% sodium hydroxide and the purified base was isolated by extraction with benzene. The extract was dried over potassium carbonate and evaporated. The oily base was obtained in yield
2.76 g. Neutralisaci kyselinou oxalovou ve směsi etheru a acetonu se získá hydrogenoxalát, který krystaluje z ethanolu a v čistém stavu taje pri 161—183 °C.2.76 g. Neutralization with oxalic acid in a mixture of ether and acetone affords the hydrogen oxalate which crystallizes from ethanol and melts in the pure state at 161-183 ° C.
Příklad 4Example 4
11- (3-DimethyIamřnopropyl) -6,ll-dihydrodibenzoi(b,e)thiepln-ll-karbonitril11- (3-Dimethylaminopropyl) -6,11-dihydrodibenzoi (b, e) thiepline-11-carbonitrile
K suspensi 1,15 g 70’% natriumamidu v 10 mililitrech benzenu se za míchání při teplotě 5 °C přikape roztok 4,75 g 6,11-dihydrodibenzo(b,e)thiepin-ll-karboňitrilu ve 25 ml benzenu a směs se míchá 2 hodiny při 90 °C. Potom se opět ochladí na 5 °C a během 5 minut se za míchání přikape roztok 3,65 gA solution of 4.75 g of 6,11-dihydrodibenzo (b, e) thiepine-11-carboitrile in 25 ml of benzene is added dropwise to a suspension of 1.15 g of 70% sodium amide in 10 ml of benzene, while stirring at 5 [deg.] C. was stirred at 90 ° C for 2 hours. It is then recooled to 5 ° C and a solution of 3.65 g is added dropwise with stirring over 5 minutes
3-dimethylaminopropylchloridu ve 20 ml etheru. Směs se potom zahřívá 5 hodin na 50 °C. Po ochlazení se rozloží 10 ml vody a extrahuje se benzenem. Benzenový surový extrakt ss dále zpracuje podobně, jak je to popsáno v předešlém příkladu. Homogenní olejovitá base se získá ve výtěžku 3,52 g (55 procent). Poskytuje hydrogenoxalát tající při 161—163 °C (ethanol-ether), identický s produktem získaným podle přechozího příkladu.Of 3-dimethylaminopropyl chloride in 20 ml of ether. The mixture was then heated at 50 ° C for 5 hours. After cooling, it is quenched with 10 ml of water and extracted with benzene. The benzene crude extract is further processed in a similar manner as described in the previous example. The homogeneous oily base was obtained in a yield of 3.52 g (55 percent). It yields hydrogen oxalate melting at 161-163 ° C (ethanol-ether), identical to the product obtained in the previous example.
Příklad 5Example 5
11-[3-( 4-Methylpiperazino) propyl]-6,11-dlhydrodibenzo (b,e )thiepin-ll-karbonitril11- [3- (4-Methylpiperazino) propyl] -6,11-dlhydrodibenzo (b, e) thiepine-11-carbonitrile
K roztoku 4,75 g 6,1.1-dihydrodibenzo(b,e)thtepin-ll-karbonitrilu ve 20 ml dimethylformamidu se v dusíkové atmosféře přidá 0,65 g 80!% olejovité suspense hydridu sodného· a směs se míchá 10 minut. PotomTo a solution of 4.75 g of 6,1,1-dihydrodibenzo (b, e) thtepine-11-carbonitrile in 20 ml of dimethylformamide was added 0.65 g of an 80% oily sodium hydride slurry under nitrogen atmosphere and the mixture was stirred for 10 minutes. Then
B se přidá 7,5 g 1,3-dibrompropanu a směs se míchá bez zahřívání 30 minut. Potom se zředí vodou a extrahuje benzenem. Benzenový roztok se promyje zředěnou kyselinou chlorovodíkovou a vodou, vysuší síranem hořečnatým a odpaří. K zbytku se přidá 10 ml 1-methylpiperazino a směs se zahřívá pod zpětným chladičem v lázni o teplotě 140 °C po dobu 7 hodin. Po ochlazení se zředí vodou a extrahuje benzenem. Extrakt se promyje vodou a potom se protřepe s přebytečnou zředěnou kyselinou chlorovodíkovou. Produkt se tím převede do vodné fáze a oddělený roztok hydrochloridu se zalkalisuje 20% hydroxidem sodným. Base se znovu isoluje extrakcí benzenem, extrakt se vysuší uhličitanem draselným- a odpaří. Získá se 5,2 g olejovité base, která se neutralisuje kyselinou maleinovou ve směsi etheru a acetonu. Získá se 7,6 g čistého bis(hydrogenmaleinátu), který krystaluje z ethanolu a taje při 170—172 qC.B 7.5 g of 1,3-dibromopropane are added and the mixture is stirred without heating for 30 minutes. It is then diluted with water and extracted with benzene. The benzene solution was washed with dilute hydrochloric acid and water, dried (MgSO4) and evaporated. To the residue was added 10 mL of 1-methylpiperazino and the mixture was heated under reflux in a 140 ° C bath for 7 hours. After cooling, it is diluted with water and extracted with benzene. The extract was washed with water and then shaken with excess dilute hydrochloric acid. The product was then transferred to the aqueous phase and the separated hydrochloride solution was made alkaline with 20% sodium hydroxide. The base was again isolated by extraction with benzene, dried over potassium carbonate and evaporated. 5.2 g of an oily base are obtained, which is neutralized with maleic acid in a mixture of ether and acetone. 7.6 g of pure bis (hydrogen maleate) are obtained, which crystallizes from ethanol and melts at 170-172 q C.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CS610681A CS219077B1 (en) | 1981-08-14 | 1981-08-14 | Derivatives of the 6,11-dihydrodibenzo/b,e/thiepin-11-carbonitrile and the salts thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CS610681A CS219077B1 (en) | 1981-08-14 | 1981-08-14 | Derivatives of the 6,11-dihydrodibenzo/b,e/thiepin-11-carbonitrile and the salts thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CS219077B1 true CS219077B1 (en) | 1983-02-25 |
Family
ID=5407326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CS610681A CS219077B1 (en) | 1981-08-14 | 1981-08-14 | Derivatives of the 6,11-dihydrodibenzo/b,e/thiepin-11-carbonitrile and the salts thereof |
Country Status (1)
| Country | Link |
|---|---|
| CS (1) | CS219077B1 (en) |
-
1981
- 1981-08-14 CS CS610681A patent/CS219077B1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3758528A (en) | Tricyclic compounds | |
| PL69767B1 (en) | 11-substituted 5 11-dihydro-6h-pyrido(2 3-b)(1 4)benzodiazepin-6-ones [us3660380a] | |
| EP0000490A1 (en) | Substituted naphthyridinones, processes for their preparations and therapeutical applications | |
| IL42799A (en) | Carbazole alcohol ether and alkanoic acid derivatives their preparation and pharmaceutical compositions containing them | |
| SU1195903A3 (en) | Method of producing 1-phenyl-2-aminocarbonylindole compounds or their salts of acid connection | |
| US3337554A (en) | Piperazino and homopiperazino-10-11-dihydrobenzo[b, f]-thiepin | |
| FI63029C (en) | EXAMINATION OF N-SUBSTITUTES FOR THE EXTRACTION OF NUTRITIONAL 5,11-DIHYDRO- (PIPERAZIN-1'-YL-ALKANOYL) -6H-PYRIDO (2,3-B) (1,4) -BENZODIAZEPIN-6-ON DERIVATE | |
| US4377695A (en) | ω-(2-Oxo-benzazolinyl)-alkanoic acid derivatives | |
| PL80395B1 (en) | Thiepino and oxepino(4 5-c)pyrrol derivatives[us3636045a] | |
| CS196893B1 (en) | 3-fluor-10-piperazino-8-substituted 10,11-dihydro-dibenzothiepines | |
| US2919271A (en) | 3-amino-1, 2-dihydro-3h-pyrido [3, 2, 1-kl]-phenothiazines | |
| CS219077B1 (en) | Derivatives of the 6,11-dihydrodibenzo/b,e/thiepin-11-carbonitrile and the salts thereof | |
| FI61029B (en) | NOW THERAPEUTIC FORM OF THERAPEUTIC THERAPEUTIC DIBENSION (B, E) (1,4) DIAZEPINER | |
| US4032648A (en) | Method and compositions containing thiochroman compounds for treating cardiac rhythm disorders | |
| US2894947A (en) | Phenthiazine derivatives | |
| US3811026A (en) | Process for benzothiepins | |
| PL136930B1 (en) | Method of obtaining novel derivatives of benzodiazepine | |
| FI62086C (en) | PROCEDURE FOR THE FRAMSTOSELLATION OF BRONCOSE SECRETERY 5,11-DIHYDRO-5H-PYRIDO (2,3-B) (1,5) BENZODIAZEPIN-5-ONER | |
| JPH0710863B2 (en) | Novel derivative of 4-OH quinolinecarboxylic acid substituted at position 2 with an etherifiable or esterifiable dihydroxy group, a process for its preparation and its use as a medicament | |
| CS247562B1 (en) | New substituted 5,10-dihydro-11h-dibenzo (b,e)(1,4)-diazepin-11-ons and method of their production | |
| US4382093A (en) | 9-Aminoalkylfluorenes | |
| US4452745A (en) | 9-Aminoalkylfluorenes | |
| US3845074A (en) | Dibenzo(b,f)thiazepin(1,4)-11-yl amino alkanoic acids | |
| US3047572A (en) | Dimethylaminophenotfflazine | |
| GB1561153A (en) | Process for the preparation of thiochroman derivatives |